; (III) limit the disclosure of pricing terms for value-based payment arrangements or capitated payment arrangements, including— (aa) payment calculations and formulas; (bb) quality measures; (cc) contract terms; (dd) payment amounts; (ee) measurement periods for all incentives; and (ff) other payment methodologies used by an entity, including a health care provider (including a health care facility), network or association of providers, service provider offering access to a network of providers, third-party administrator, or pharmacy benefit manager; (IV) limit the disclosure of overpayments and overpayment recovery terms; (V) limit the right of the responsible plan fiduciary to select an auditor; (VI) otherwise limit or unduly delay by greater than 60 calendar days after the date of request the responsible plan fiduciary from auditing all de-identified claims and encounter information or data